Janux Therapeutics is a biopharmaceutical company engaged in the development of a pipeline of immunotherapies by applying Co.'s proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and TRACIr platforms to treat patients suffering from cancer. Co.'s initial focus is on developing a class of T cell engagers, and Co.'s primary product candidates are designed to target clinically validated drug targets. Co. is developing a pipeline with programs targeting prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2, with all of Co.'s programs in the preclinical or discovery stage. The JANX average annual return since 2021 is shown above.
The Average Annual Return on the JANX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether JANX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the JANX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|